{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:02:52Z","timestamp":1785578572132,"version":"3.56.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Obstetrics and Gynecology Clinics of North America"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.ogc.2009.08.001","type":"journal-article","created":{"date-parts":[[2009,11,21]],"date-time":"2009-11-21T11:51:15Z","timestamp":1258804275000},"page":"493-507","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacologic Management of Urinary Incontinence, Voiding Dysfunction, and Overactive Bladder"],"prefix":"10.1016","volume":"36","author":[{"given":"Emily K.","family":"Saks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily A.","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 6A","key":"10.1016\/j.ogc.2009.08.001_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0090-4295(97)00587-6","article-title":"A neurologic basis for the overactive bladder","volume":"50","author":"de Groat","year":"1997","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ogc.2009.08.001_bib2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0002-9378(94)70346-9","article-title":"Structural support of the urethra as it relates to stress urinary incontinence: the hammock hypothesis","volume":"170","author":"DeLancey","year":"1994","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.ogc.2009.08.001_bib3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1464-410X.2003.04161.x","article-title":"Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence","volume":"91","author":"Fraser","year":"2003","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ogc.2009.08.001_bib4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/0090-4295(75)90113-2","article-title":"Ephedrine in treatment of urinary incontinence","volume":"5","author":"Diokno","year":"1975","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ogc.2009.08.001_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004742.pub2","article-title":"Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults","author":"Mariappan","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ogc.2009.08.001_bib6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s002400100175","article-title":"Clinical options for imipramine in the management of urinary incontinence","volume":"29","author":"Hunsballe","year":"2001","journal-title":"Urol Res"},{"issue":"5","key":"10.1016\/j.ogc.2009.08.001_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ageing\/15.5.299","article-title":"Double-blind study of imipramine and placebo for incontinence due to bladder instability","volume":"15","author":"Castleden","year":"1986","journal-title":"Age Ageing"},{"issue":"5","key":"10.1016\/j.ogc.2009.08.001_bib8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s001920170032","article-title":"The use of short-form quality of life questionnaires to measure the impact of imipramine on women with urge incontinence","volume":"12","author":"Woodman","year":"2001","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"2","key":"10.1016\/j.ogc.2009.08.001_bib9","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0022-3565(25)10548-X","article-title":"Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat","volume":"274","author":"Thor","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.ogc.2009.08.001_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0029-7844(03)00376-4","article-title":"Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response","volume":"102","author":"Bump","year":"2003","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ogc.2009.08.001_bib11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1464-410X.2007.06980.x","article-title":"Duloxetine compared with placebo for treating women with symptoms of overactive bladder","volume":"100","author":"Steers","year":"2007","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ogc.2009.08.001_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1067\/mob.2002.124840","article-title":"Duloxetine versus placebo in the treatment of stress urinary incontinence","volume":"187","author":"Norton","year":"2002","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ogc.2009.08.001_bib13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1464-410X.2008.07577.x","article-title":"Long-term efficacy of duloxetine in women with stress urinary incontinence","volume":"102","author":"Bump","year":"2008","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003781.pub2","article-title":"Anticholinergic drugs versus placebo for overactive bladder syndrome in adults","author":"Nabi","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ogc.2009.08.001_bib15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0094-0143(02)00053-8","article-title":"Pharmacologic management of urinary incontinence in women","volume":"29","author":"Wein","year":"2002","journal-title":"Urol Clin North Am"},{"issue":"5","key":"10.1016\/j.ogc.2009.08.001_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","article-title":"Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder","volume":"148","author":"Abrams","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003190.pub4","article-title":"Anticholinergic drugs versus other medications for overactive bladder syndrome in adults","author":"Roxburgh","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.ogc.2009.08.001_bib18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0022-5347(05)68810-6","article-title":"Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group","volume":"161","author":"Anderson","year":"1999","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ogc.2009.08.001_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/PL00007103","article-title":"Oxybutynin and the overactive bladder","volume":"19","author":"Andersson","year":"2001","journal-title":"World J Urol"},{"issue":"Suppl 2","key":"10.1016\/j.ogc.2009.08.001_bib20","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1038\/sj.bjp.0706560","article-title":"Muscarinic receptors in the bladder: from basic research to therapeutics","volume":"147","author":"Hegde","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.ogc.2009.08.001_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/A:1022259011052","article-title":"Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system","volume":"20","author":"Zobrist","year":"2003","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.ogc.2009.08.001_bib22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.ogc.2009.08.001_bib23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0090-4295(03)00356-X","article-title":"Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence","volume":"62","author":"Dmochowski","year":"2003","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib24","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.juro.2008.11.125","article-title":"Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study","volume":"181","author":"Staskin","year":"2009","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ucl.2006.06.003","article-title":"Oxybutynin in detrusor overactivity","volume":"33","author":"Diokno","year":"2006","journal-title":"Urol Clin North Am"},{"issue":"3","key":"10.1016\/j.ogc.2009.08.001_bib26","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ogc.2009.08.001_bib27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1464-410x.2000.00575.x","article-title":"Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial","volume":"85","author":"Cardozo","year":"2000","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ucl.2006.06.006","article-title":"Trospium chloride: distinct among other anticholinergic agents available for the treatment of overactive bladder","volume":"33","author":"Staskin","year":"2006","journal-title":"Urol Clin North Am"},{"issue":"21","key":"10.1016\/j.ogc.2009.08.001_bib29","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2165\/00003495-200464210-00005","article-title":"Trospium chloride in the management of overactive bladder","volume":"64","author":"Rovner","year":"2004","journal-title":"Drugs"},{"issue":"5 Pt 1","key":"10.1016\/j.ogc.2009.08.001_bib30","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.ogc.2009.08.001_bib31","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00002512-200522120-00005","article-title":"Solifenacin in overactive bladder syndrome","volume":"22","author":"Simpson","year":"2005","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.ogc.2009.08.001_bib32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib33","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2004.01.008","article-title":"Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder","volume":"45","author":"Haab","year":"2004","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1517\/14656566.8.4.511","article-title":"Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder","volume":"8","author":"Zinner","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib35","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eururo.2007.07.009","article-title":"Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder","volume":"52","author":"Chapple","year":"2007","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ogc.2009.08.001_bib36","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1016\/j.juro.2007.08.033","article-title":"Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome","volume":"178","author":"Nitti","year":"2007","journal-title":"J Urol"},{"issue":"Suppl 2","key":"10.1016\/j.ogc.2009.08.001_bib37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.urology.2006.05.043","article-title":"The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis","volume":"68","author":"Khullar","year":"2006","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ogc.2009.08.001_bib38","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/AOG.0b013e31818e8aa4","article-title":"Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms","volume":"112","author":"Gopal","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"Suppl 4","key":"10.1016\/j.ogc.2009.08.001_bib39","first-page":"S121","article-title":"Persistence with overactive bladder pharmacotherapy in a Medicaid population","volume":"11","author":"Shaya","year":"2005","journal-title":"Am J Manag Care"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib40","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1524-4733.2005.00041.x","article-title":"Persistence and adherence of medications for chronic overactive bladder\/urinary incontinence in the California Medicaid program","volume":"8","author":"Yu","year":"2005","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.ogc.2009.08.001_bib41","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1471-0528.1997.tb12054.x","article-title":"A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance","volume":"104","author":"Kelleher","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"issue":"3","key":"10.1016\/j.ogc.2009.08.001_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005429","article-title":"Which anticholinergic drug for overactive bladder symptoms in adults","author":"Hay-Smith","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ogc.2009.08.001_bib43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib44","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1464-410X.2006.06658.x","article-title":"Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study","volume":"99","author":"Sand","year":"2007","journal-title":"BJU Int"},{"issue":"9","key":"10.1016\/j.ogc.2009.08.001_bib45","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1464-410x.1999.00373.x","article-title":"Visual hallucinations at the onset of tolterodine treatment in a patient with a high-level spinal cord injury","volume":"84","author":"Malavaud","year":"1999","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ogc.2009.08.001_bib46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","article-title":"Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects","volume":"50","author":"Kay","year":"2006","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ogc.2009.08.001_bib47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjopharm.2006.03.004","article-title":"Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis","volume":"4","author":"Wagg","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"issue":"3 Pt 1","key":"10.1016\/j.ogc.2009.08.001_bib48","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/00005392-200009010-00018","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results","volume":"164","author":"Schurch","year":"2000","journal-title":"J Urol"},{"issue":"Suppl 6","key":"10.1016\/j.ogc.2009.08.001_bib49","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/nau.20479","article-title":"Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms","volume":"26","author":"Cruz","year":"2007","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"10.1016\/j.ogc.2009.08.001_bib50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","article-title":"Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review","volume":"53","author":"Karsenty","year":"2008","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ogc.2009.08.001_bib51","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","article-title":"Refractory idiopathic urge urinary incontinence and botulinum A injection","volume":"180","author":"Brubaker","year":"2008","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ogc.2009.08.001_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005493.pub2","article-title":"Botulinum toxin injections for adults with overactive bladder syndrome","author":"Duthie","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ogc.2009.08.001_bib53","article-title":"Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report","author":"Apostolidis","year":"2008","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ogc.2009.08.001_bib54","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2008.08.048","article-title":"Six-year follow-up of botulinum toxin a intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results","volume":"55","author":"Giannantoni","year":"2009","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ogc.2009.08.001_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00005392-199907000-00002","article-title":"Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder","volume":"162","author":"Chancellor","year":"1999","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ogc.2009.08.001_bib56","first-page":"79","article-title":"New therapeutic options for refractory neurogenic detrusor overactivity","volume":"56","author":"Giannantoni","year":"2004","journal-title":"Minerva Urol Nefrol"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib57","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MOU.0b013e32832ce8a4","article-title":"Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence","volume":"19","author":"Andersson","year":"2009","journal-title":"Curr Opin Urol"},{"issue":"155","key":"10.1016\/j.ogc.2009.08.001_bib58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1742-1241.2007.01247.x","article-title":"Novel uses for antidiuresis","author":"Hashim","year":"2007","journal-title":"Int J Clin Pract Suppl"},{"issue":"5","key":"10.1016\/j.ogc.2009.08.001_bib59","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.juro.2008.07.050","article-title":"Investigating the associations between nocturia and sleep disorders in perimenopausal women","volume":"180","author":"Gopal","year":"2008","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ogc.2009.08.001_bib60","first-page":"24","article-title":"Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study","volume":"71","author":"Dykstra","year":"1990","journal-title":"Arch Phys Med Rehabil"},{"issue":"1","key":"10.1016\/j.ogc.2009.08.001_bib61","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0302-2838(02)00209-9","article-title":"Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease","volume":"42","author":"de Seze","year":"2002","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib62","first-page":"1107","article-title":"Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction","volume":"165","author":"Phelan","year":"2001","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ogc.2009.08.001_bib63","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0022-5347(05)68947-1","article-title":"Diagnosing bladder outlet obstruction in women","volume":"161","author":"Nitti","year":"1999","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ogc.2009.08.001_bib64","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/S0022-5347(05)68101-3","article-title":"Management of functional bladder neck obstruction in women: use of alpha-blockers and pediatric resectoscope for bladder neck incision","volume":"162","author":"Kumar","year":"1999","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib65","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.juro.2007.11.060","article-title":"Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial","volume":"179","author":"Low","year":"2008","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.ogc.2009.08.001_bib66","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/j.1532-5415.2006.00917.x","article-title":"Detrusor underactivity: clinical features and pathogenesis of an underdiagnosed geriatric condition","volume":"54","author":"Taylor","year":"2006","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"10.1016\/j.ogc.2009.08.001_bib67","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0022-5347(17)47234-X","article-title":"Is bethanechol chloride clinically effective in promoting bladder emptying? A literature review","volume":"134","author":"Finkbeiner","year":"1985","journal-title":"J Urol"},{"issue":"22","key":"10.1016\/j.ogc.2009.08.001_bib68","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1001\/jama.257.22.3076","article-title":"Detrusor hyperactivity with impaired contractile function: an unrecognized but common cause of incontinence in elderly patients","volume":"257","author":"Resnick","year":"1987","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ogc.2009.08.001_bib69","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0090-4295(02)02541-4","article-title":"Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity","volume":"61","author":"Kuo","year":"2003","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ogc.2009.08.001_bib70","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0950-3552(96)80022-8","article-title":"Urogenital effects of the menopause","volume":"10","author":"Schaffer","year":"1996","journal-title":"Baillieres Clin Obstet Gynaecol"},{"issue":"10","key":"10.1016\/j.ogc.2009.08.001_bib71","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.0001-6349.2004.00581.x","article-title":"A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder","volume":"83","author":"Cardozo","year":"2004","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"10.1016\/j.ogc.2009.08.001_bib72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s001920170088","article-title":"A systematic review of estrogens for recurrent urinary tract infections: third report of the Hormones and Urogenital Therapy (HUT) Committee","volume":"12","author":"Cardozo","year":"2001","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"8","key":"10.1016\/j.ogc.2009.08.001_bib73","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jama.293.8.935","article-title":"Effects of estrogen with and without progestin on urinary incontinence","volume":"293","author":"Hendrix","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ogc.2009.08.001_bib74","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0029-7844(00)01115-7","article-title":"Postmenopausal hormones and incontinence: the Heart and Estrogen\/Progestin Replacement Study","volume":"97","author":"Grady","year":"2001","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003193.pub3","article-title":"Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults","author":"Alhasso","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ogc.2009.08.001_bib76","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-149-3-200808050-00005","article-title":"Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial","volume":"149","author":"Burgio","year":"2008","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.ogc.2009.08.001_bib77","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1517\/14728214.13.3.431","article-title":"Emerging drugs for treatment of overactive bladder and detrusor overactivity","volume":"13","author":"Drake","year":"2008","journal-title":"Expert Opin Emerg Drugs"},{"issue":"4","key":"10.1016\/j.ogc.2009.08.001_bib80","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2125.2006.02597.x","article-title":"Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebo-controlled, randomized study","volume":"61","author":"Safarinejad","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"6 Pt 1","key":"10.1016\/j.ogc.2009.08.001_bib81","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.juro.2006.08.018","article-title":"Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence","volume":"176","author":"Green","year":"2006","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ogc.2009.08.001_bib82","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","article-title":"Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability","volume":"20","author":"Halaska","year":"2003","journal-title":"World J Urol"},{"issue":"9","key":"10.1016\/j.ogc.2009.08.001_bib83","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1464-410X.2008.07907.x","article-title":"Comparison of fesoterodine and tolterodine in patients with overactive bladder","volume":"102","author":"Chapple","year":"2008","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ogc.2009.08.001_bib84","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1517\/13543784.10.1.65","article-title":"Pharmacological agents for the treatment of urinary incontinence due to overactive bladder","volume":"10","author":"Wein","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ogc.2009.08.001_bib85","series-title":"Urogynecology and reconstructive surgery","first-page":"33","article-title":"Neurophysiology and pharmacology of the lower urinary tract","author":"Benson","year":"2007"}],"container-title":["Obstetrics and Gynecology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854509000667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854509000667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T10:41:51Z","timestamp":1739443311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889854509000667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0889854509000667"],"URL":"https:\/\/doi.org\/10.1016\/j.ogc.2009.08.001","relation":{},"ISSN":["0889-8545"],"issn-type":[{"value":"0889-8545","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}